Stability and prognostic value of B-cell markers in primary Sjögren’s syndrome: results from the French ASSESS cohort
Clicks: 1
ID: 319290
2026
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
0.0
/100
1 views
0 readers
AI Quality Assessment
Not analyzed
Readership in this journal
Ranked #159 of 198 articles by views in Lara D. Veeken
Most read
Least read
Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 198 in total.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Abstract OBJECTIVES To characterize the longitudinal evolution of B cell biomarkers in patients with primary Sjögren’s disease (SjD) and analyse their association with the clinical disease course. METHODS We analysed data from the French multicentre prospective ASSESS cohort. Patients fulfilling AECG criteria with ≥2 visits including both immunological assessments and ClinESSDAI scores over a 5 years follow-up were included. Baseline B cell biomarkers included immunoglobulin levels, monoclonal component, cryoglobulinaemia, complement fractions, rheumatoid factor and β2-microglobulin. Disease activity was assessed using ClinESSDAI score. Associations between the number of abnormal B cell markers and disease activity were analysed using ANOVA and Kruskal–Wallis tests. Changes in IgG were evaluated according to the biological domain of the STAR index, defined as a relative decrease ≥10%. RESULTS Among the 395 ASSESS participants, 362 met inclusion criteria. Mean follow-up was 56.4 months (±10.6), with a mean of 5.3 visits per patient (±0.5). B cell biomarkers remained stable in 80.5%. According to STAR criteria, 43.1% were classified as biological responders to the biological domain of STAR based on IgG decrease, occurring mostly within the first year, without correlation with changes in ClinESSDAI or ESSPRI. Although baseline ClinESSDAI did not differ by the number of B cell abnormalities (p= 0.096), patients with multiple B cell activity markers—particularly ≥5—had an increased risk of persistent or worsening disease (OR 4.6, 95% CI 1.2–17.8; p= 0.002). CONCLUSION B cell biomarkers profile in SjD is largely stable over time. However, a high baseline “B cell burden” identifies patients at risk of poorer outcomes, supporting their use for stratification and monitoring.
| Reference Key |
openalex_W7166843764
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Paulina Szafors, Cedric Lukas, Bernard Combe, Jacques-Eric Gottenberg, Xavier Mariette, Raphaèle Séror, Jacques Morel |
| Journal | Lara D. Veeken |
| Year | 2026 |
| DOI |
10.1093/rheumatology/keag339
|
| URL | |
| Keywords | Keywords not found |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.